Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, filing, pharmaceuticals
TL;DR
Telomir Pharma filed an 8-K, looks like routine admin stuff, no big news.
AI Summary
On June 11, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns administrative details and does not disclose any new material events, financial results, or significant corporate actions. The company is based in Miami, Florida, and operates in the pharmaceutical preparations industry.
Why It Matters
This 8-K filing indicates no new material events or updates from Telomir Pharmaceuticals, suggesting a period of routine operations or administrative filings.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no disclosed material events, indicating low immediate risk from this specific filing.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- June 11, 2025 (date) — Date of earliest event reported
- Miami, Florida (location) — Principal Executive Offices
- 786-396-6723 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Telomir Pharmaceuticals, Inc.?
The filing is a Current Report on Form 8-K, indicating the date of the earliest event reported is June 11, 2025, and it is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Telomir Pharmaceuticals, Inc.'s state of incorporation and fiscal year end?
Telomir Pharmaceuticals, Inc. is incorporated in Florida and its fiscal year ends on December 31.
What is the business address and phone number for Telomir Pharmaceuticals, Inc.?
The business address is 100 SE 2nd St, Suite 2000, #1009, Miami, Florida 33131, and the telephone number is (786) 396-6723.
What is the Standard Industrial Classification (SIC) code for Telomir Pharmaceuticals, Inc.?
The SIC code for Telomir Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Does this 8-K filing disclose any new material events or financial results?
Based on the provided text, this 8-K filing appears to be primarily administrative and does not explicitly disclose any new material events, financial results, or significant corporate actions.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding Telomir Pharmaceuticals, Inc. (TELO).